Provided by Tiger Trade Technology Pte. Ltd.

Incyte

90.30
-1.9600-2.12%
Post-market: 90.300.00000.00%19:56 EDT
Volume:1.49M
Turnover:135.74M
Market Cap:17.97B
PE:14.09
High:92.50
Open:92.28
Low:90.20
Close:92.26
52wk High:112.29
52wk Low:53.56
Shares:199.01M
Float Shares:163.04M
Volume Ratio:0.77
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):6.41
EPS(LYR):6.41
ROE:29.87%
ROA:13.57%
PB:3.48
PE(LYR):14.09

Loading ...

Incyte President, R&D Pablo J Cagnoni disposed of USD 1.76 million in common shares

Reuters
·
Mar 20

Knight Therapeutics Inc. publishes 2025 annual report reporting CAD 450.09 million revenue and 21% growth

Reuters
·
Mar 19

Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Mar 19

Assessing Incyte (INCY) Valuation As Short Term Returns Soften But Longer Term Gains Remain Strong

Simply Wall St.
·
Mar 18

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Mar 18

BRIEF-Knight Therapeutics Announces Approval Of Additional Indication For Minjuvi® (Tafasitamab) In Brazil

Reuters
·
Mar 17

Knight Therapeutics Announces Approval of Additional Indication for Minjuvi® (Tafasitamab) in Brazil

THOMSON REUTERS
·
Mar 17

Knight Therapeutics Announces Regulatory Supplemental Submission of Minjuvi® (Tafasitamab) for Follicular Lymphoma in Argentina and Mexico

THOMSON REUTERS
·
Mar 17

Incyte Cut to Hold From Buy by Jefferies

Dow Jones
·
Mar 16

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Cogent Biosciences, Summit Therapeutics

Reuters
·
Mar 16

Incyte Corp. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
Mar 13

Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
Mar 11

Incyte Corp. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Mar 10

Analysts’ Top Healthcare Picks: Revolution Medicines (RVMD), Incyte (INCY)

TIPRANKS
·
Mar 09

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (OtherRHHVF), Incyte (INCY) and Oncology Institute (TOI)

TIPRANKS
·
Mar 09

Incyte Price Target Maintained With a $135.00/Share by HC Wainwright & Co.

Dow Jones
·
Mar 09

Incyte Says FDA Declines Supplemental Biologics Application for Zynyz Injection

MT Newswires Live
·
Mar 09

Balancing Post‑Jakafi Opportunities and Execution Risks: Rationale Behind a Neutral Stance on Incyte

TIPRANKS
·
Mar 07

Incyte Faces FDA Setback on Zynyz Lung Cancer Expansion

TIPRANKS
·
Mar 07

BRIEF-Incyte - FDA Issues Complete Response Letter For Zynyz Sbla In Nsclc - SEC Filing

Reuters
·
Mar 07